Yakup Bozkaya

Yakup Bozkaya

Auto-generated profile, based on publicly available information

Yakup Bozkaya

Department of Medical Oncology, Gaziosmanpaşa Hastanesi, Istinye University, 34010 Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2019 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
YBYakup Bozkaya
Yakup Bozkaya
BKBediz Kurt
Bediz Kurt
FGFatih Gürler
Fatih Gürler

20 June 2018 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
YBYakup Bozkaya
Yakup Bozkaya
GEGökmen Umut Erdem
Gökmen Umut Erdem
NDNebi Serkan Demirci
Nebi Serkan Demirci
OYOzan Yazıcı
Ozan Yazıcı
NÖNuriye Yıldırım Özdemir
Nuriye Yıldırım Özdemir
NZNurullah Zengin
Nurullah Zengin
Aim: The aim of this study was to evaluate the prognostic importance of the albumin to globulin ratio (AGR) in terms of overall survival (OS) and progression free survival (PFS) in metastatic gastric cancer patients. Methods: The patients diagnosed with metastatic gastric cancer between 2009 and April 2016 at the hospital have been studied retrospectively. The clinicopathological characteristics, laboratory, and treatment parameters have been assessed. AGR value has been calculated using the following formula (AGR = serum albumin/total protein − serum albumin). Results: In total, 251 patients were included in the study population. The median value of AGR was 1.206 (range = 0.460–3.130), and the cut-off value was set as 1.20. Based on the cut-off value, 126 patients were categorized in the low AGR group, while the remaining 125 patients were categorized in the high AGR group. ECOG (Eastern Cooperative Oncology Group) performance scores, CEA levels, CA19-9 levels, hemoglobin levels, lactate dehydrogenase levels, and liver metastasis ratios varied significantly between the low and high AGR groups (p < .05). The Kaplan-Meier curve has shown that, compared to the low AGR group, the high AGR group has better OS (12.2 vs 9.3 months, p = .002) and better PFS (8.0 vs 5.7 months, p < .001) rates. The univariate and multivariate analyses also proved that low AGR is an independent bad risk factor in metastatic gastric cancer patients, both in terms of OS (p = .019, Hazard Ratio (HR) = 1.380, 95% Confidence Interval (CI) = 1.055–1.805) and PFS (p = .002, HR = 1.514, 95% CI = 1.164–1.968). Conclusion: In metastatic gastric cancer patients, AGR is an independent prognostic factor for OS and PFS. Thus, in this patient group, the low cost albumin and globulin which can be measured with routine clinical practice may be used as an appropriate prognostic tool.

20 March 2017 in Journal of Obstetrics and Gynaecology
Verified
Journal Article
Closed access
YBYakup Bozkaya
Yakup Bozkaya
MDMutlu Doğan
Mutlu Doğan
GEGökmen Umut Erdem
Gökmen Umut Erdem
GTGökhan Tulunay
Gökhan Tulunay
HUHikmet Uncu
Hikmet Uncu
NZNurullah Zengin
Nurullah Zengin
The aim of this study was to evaluate the efficacy and toxicity profile of oral etoposide (50 mg/day, days 1–14, every 3 weeks) in recurrent platinum-resistant epithelial ovarian cancer (EOC). 52 recurrent platinum-resistant EOC patients followed up in four centres between April 2000 and December 2013 were analysed retrospectively. There was response in a total of 21 patients [partial response (PR) and stable disease (SD)], 12 of them used etoposide in second and third, and 9 of them used it in fourth- to fifth-lines of treatment. The overall response rate was 19.2% and clinical benefit rate was 40.4% [PR (19.2%), SD (21.2%)]. Median overall survival (OS) and progression-free survival (PFS) was 9.95 months (95%CI, 0.2–19.7 months) and 3.2 months (95%CI 2.6–3.8 months), respectively. Grade III–IV haematologic and non-haematologic adverse events were observed in 7 (13.4%) patients. We consider that oral etoposide (50 mg/day, days 1–14, every 3 weeks) is an effective treatment with a manageable adverse effect profile in recurrent platinum-resistant EOC patients.

30 August 2019 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
YBYakup Bozkaya
Yakup Bozkaya
OKOsman Köstek
Osman Köstek
ASAbdullah Sakin
Abdullah Sakin
DÖDeniz Tataroğlu Özyükseler
Deniz Tataroğlu Özyükseler
TŞTeoman Şakalar
Teoman Şakalar
IÇİbRahim Çil
İbRahim Çil

4 February 2019 in Expert Review of Molecular Diagnostics
Verified
Journal Article
Closed access
YBYakup Bozkaya
Yakup Bozkaya
OYOzan Yazıcı
Ozan Yazıcı
Background: The prognostic significance of serum gamma-glutamyl transferase (GGT) level at diagnosis in patients with metastatic non-small lung cancer (NSCLC) is not clear. We aimed to assess the relationship between serum GGT level and overall survival (OS) and progression-free survival (PFS) in this patient population. Methods: Data of patients with metastatic NSCLC who were admitted to the medical oncology clinic of our hospital during April 2013–December 2017 were retrospectively analyzed. Patients were divided into two groups based on GGT levels, normal and high (as defined by normal reference levels), and then compared. Results: Significant differences between the high and normal GGT level groups were found regarding female sex, Eastern Cooperative Oncology Group performance score, weight loss at the time of diagnosis, and lactate dehydrogenase level (p < 0.05). The high GGT group had a shorter median OS (11.5 vs. 3.4 months, p < 0.001) and PFS (7.8 vs. 3.0 months, p = 0.001). High GGT level is an independent risk factor for OS (hazard ratio [HR] 2.270; 95% confidence interval [CI], 1.398–3.686; p < 0.001) and PFS (HR 2.489; 95% CI, 1.323–4.684; p = 0.005). Conclusions: High serum GGT level is an independent prognostic factor for OS and PFS in metastatic NSCLC patients.

8 June 2017 in Molecular and Clinical Oncology
Verified
Journal Article
Open access
PDF file
YBYakup Bozkaya
Yakup Bozkaya
NDNebi Serkan Serkan Demirci
Nebi Serkan Serkan Demirci
AKAli̇can Kurti̇pek
Ali̇can Kurti̇pek
GEGökmen Umut Erdem
Gökmen Umut Erdem
NONuri̇ye Yildirim Ozdemi̇r
Nuri̇ye Yildirim Ozdemi̇r
NZNurullah Zengin
Nurullah Zengin
The aim of the present study was to determine whether there are any clinicopathological or prognostic differences between patients with α-fetoprotein-secreting gastric carcinoma (AFP-SGC) and non-AFP-SGC. Pathological parameters, clinical parameters, and treatment efficacy were compared in patients with AFP-SGC and non-AFP-SGC. In total, 362 patients (53 with AFP-SGC and 309 with non-AFP-SGC) were included in the present study. Patients with AFP-SGC had significantly higher levels of lymphovascular invasion, perineural invasion (PNI), rate of liver metastasis, and stage IV cancer compared with patients with non-AFP-SGC (P<0.05). The median overall survival (OS) rate was 12.6 months in the AFP-SGC group, and 22.1 months in the non-AFP-SGC group (P<0.001). The median OS and disease free survival (DFS) of patients with stage I–III AFP-SGC were 28.1 and 13.4 months, respectively, whereas for patients with non-AFP-SGC, the OS and DFS were 45.3 and 38.0 months, respectively (P=0.01; P=0.02). The median OS for the stage IV AFP-SGC and non-AFP-SGC groups was 9.3 and 11.5 months, respectively (P=0.14). Multivariate analysis of the entire patient group revealed that the Eastern Cooperative Oncology Group (ECOG) performance score of ≥2, lymph node involvement, presence of PNI, high levels of carcinoembryonic antigen, and distant metastasis were significantly correlated with OS. The lymph node involvement, ECOG performance score of ≥2, AFP-SGC type, and weight loss at diagnosis were also significant factors influencing the DFS in the stage I–III group. In conclusion, patients with AFP-SGC had more aggressive clinicopathological features and biological behavior with an increased tendency of liver metastasis compared with patients with non-AFP-SGC. In the near future, AFP may become an important surrogate marker to manage therapies of patients with gastric cancer.